CSI Market
Sign In | Register

Moonlake Immunotherapeutics (MLTX) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access MLTX quarterly Cash Flow →
Quarterly cash flow trends provide additional context on Moonlake Immunotherapeutics's liquidity and ability to support ongoing operations and capital needs.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-230.32
Depreciation & amortization2.62
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation12.90
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Payment Of Formation Costs Through Issuance Of Class B Ordinary Shares-
Research And Development In Process Share Based Portion-
Increase Decrease In Operating Lease Right Of Use Asset-
Increase Decrease In Operating Lease Liability-0.06
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Other Receivables-2.03
Increase (Decrease) in Accounts Payable20.56
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities2.59
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense0.56
Other Working Capital-0.59
Other Noncash Income (Expense)-1.02
Other net0.00
Payments for (Proceeds from) Other Operating Activities-1.22
Discontinued operations0.00
Net Cash flow from Operating Activities-196.01
Investing Activities
Capital Expenditures-0.04
Sale of Capital Items0.00
Proceeds from Maturities, Prepayments and Calls of Available-for-sale Securities468.40
Payments to Acquire Available-for-sale Securities, Debt-265.37
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities202.99
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings73.02
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock72.88
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-180.33
Capital Contribution P I P E-
Proceeds From Reverse Recapitalization-
Proceeds From Contribution From Par Value Of Common Stock-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents180.43
Payments Of Stamp Duty-
Right Of Use Asset Obtained In Exchange For Operating Lease Liability-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities146.00
Effect of exchange rate on cash flow1.11
Discontinued operations0.00
Free Cash Flow-196.04
Total Cash Flow154.09
4 historic quarters locked

Sign in to unlock the full Moonlake Immunotherapeutics cash flow history.

Sign In Create Free Account

About Moonlake Immunotherapeutics Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: February 25, 2026
  • Source: mnlk-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001821586-26-000002

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License